Adolescent gender dysphoria: What is the evidence for medical interventions

This meeting will explore the evidence for intervention with medical hormonal therapy in adolescents with gender dysphoria and the effects of this approach.

The use of gonadotropin-releasing hormone (GnRH) agonists (more commonly known as hormone or puberty blockers) in transgender adolescents is a contentious topic in regards to the ethics of treating children, evidence-based medicine and long term effects.

The early use of blockers has been suggested as reversible but as treatment of this group increases, issues and challenges in regards to fertility preservation and the effects of future gender reassignment surgery, cognitive and bone health have been highlighted.

This area is very controversial, in society and medical practice, with a judicial review ongoing together with a NICE Review of Evidence. In addition, there is a High Court Case challenging the Gillick Competency in adolescents.

This meeting will provide a balanced and informed debate into the current practice affecting medical practitioners from urology, gynaecology, endocrinology and psychiatry.

Topics include:

• The evidence for medical intervention in adolescent dysphoria
• Highlight and understand the controversies in this area
• The roles of all gender identity specialists in adolescent dysphoria
• Provide a template for future research and management in this challenging area

*Please note we will need to check all GMC numbers of attendees to this meeting. Ensure you bring this with you, attendance may be denied otherwise. 

The Urology Section would like to thank our Annual Sponsor KARL STORZ Endoscopy (UK) Ltd for their valued support of the entire 2021 to 2022 Academic Programme.

Please note that the scientific programme and content has not been influenced in any way by the sponsors.

Follow us on:

Facebook 
Instagram
LinkedIn
Twitter
YouTube